Squamous cell carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Frequent inactivation of RUNX3 by promoter hypermethylation and protein mislocalization in oral squamous cell carcinomas.
|
19015875 |
2009 |
Squamous cell carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
On the contrary, methylation of APC and RUNX3 was more frequent in adenocarcinomas than in squamous cell carcinomas (P < 0.05).
|
12841866 |
2003 |
Squamous cell carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The western blotting experiments showed that RUNX3 was not expressed in normal skin tissues, but it was overexpressed in all MM and SCC samples, and in five of the six BCC samples.
|
21623876 |
2011 |
Squamous cell carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
RUNX3 methylation was significantly more frequent in non-smokers (16/43, 37.2%) than smokers (12/71, 16.9%; p=0.014), and in patients with AdC (26/72, 36.1%) than in patients with SqC (3/45, 6.7%; p<0.001).
|
16328045 |
2006 |
Squamous cell carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Frequent silencing of RUNX3 in esophageal squamous cell carcinomas is associated with radioresistance and poor prognosis.
|
17384682 |
2007 |
Squamous cell carcinoma
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
Differential expression of RUNX genes in human esophageal squamous cell carcinoma: downregulation of RUNX3 worsens patient prognosis.
|
18500170 |
2007 |
Squamous cell carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, the hypermethylation of RASSF1A or RUNX3 gene is therefore a useful biomarker to predict the prognosis in NSCLC, particularly RASSF1A due to SCCs and RUNX3 due to ACs.
|
17606310 |
2007 |
Squamous cell carcinoma
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
Decreased expression of RUNX3 is correlated with tumor progression and poor prognosis in patients with esophageal squamous cell carcinoma.
|
18288406 |
2008 |
Squamous cell carcinoma
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
This study examined the expression of RUNX3 protein in human esophageal mucosa and squamous cell carcinoma in comparison with clinicopathological profiles.
|
16582583 |
2005 |
Squamous cell carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Folate concentrations and methylation of LINE-1, RASSF1, and RUNX3 were significantly higher in adenocarcinoma compared to squamous cell carcinoma (SCC).
|
19764999 |
2009 |
Squamous cell carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Loss of RUNX3 expression inhibits bone invasion of oral squamous cell carcinoma.
|
28030842 |
2017 |
Squamous cell carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The pooled OR was obtained from eleven studies including 271 squamous cell carcinoma and 389 adenocarcinoma (OR 0.41, confidence interval 0.19-0.89, P=0.02), which indicated that RUNX3 hypermethylation is significantly higher in adenocarcinoma that in squamous cell carcinoma.
|
26082616 |
2015 |
Squamous cell carcinoma
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
Promoter hypermethylation of the RUNX3 gene in esophageal squamous cell carcinoma.
|
18058463 |
2007 |
Squamous cell carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Our results showed two hypomethylated genes (CDKN2A and MGMT) and three hypermethylated genes (CDH13, RUNX3 and APC) in ACs compared with SCCs.
|
26862903 |
2016 |
Squamous cell carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
RUNX3 plays a tumor suppressor role by inhibiting cell migration, invasion and angiogenesis in oral squamous cell carcinoma.
|
28765934 |
2017 |
Squamous cell carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The present study aimed to determine the status of RUNX3 protein expression and its association with clinicopathological characteristics in tongue squamous cell carcinomas (SCC).
|
30535462 |
2019 |
Squamous cell carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The methylation status of CDKN2A (cyclin-dependent kinase inhibitor 2A or p16), SFN (stratifin or 14-3-3 σ), EDNRB (endothelin receptor B) and RUNX3 (runt-related transcript factor-3) was evaluated by MSP (Methylation-Specific Polymerase Chain Reaction) analysis in non-neoplastic oral epithelial cells from OSCC patients (n = 70) and cancer-free subjects (n = 41).
|
21380558 |
2011 |